MX2009004027A - Anticuerpos anti factor de crecimiento endotelial vascular completamente humanos y metodos de uso. - Google Patents

Anticuerpos anti factor de crecimiento endotelial vascular completamente humanos y metodos de uso.

Info

Publication number
MX2009004027A
MX2009004027A MX2009004027A MX2009004027A MX2009004027A MX 2009004027 A MX2009004027 A MX 2009004027A MX 2009004027 A MX2009004027 A MX 2009004027A MX 2009004027 A MX2009004027 A MX 2009004027A MX 2009004027 A MX2009004027 A MX 2009004027A
Authority
MX
Mexico
Prior art keywords
vegf
fully human
methods
human anti
angiogenesis
Prior art date
Application number
MX2009004027A
Other languages
English (en)
Inventor
Linda Masat
Walter Robert Bishop
Chao Bai Huang
Suman Ramachandra
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2009004027A publication Critical patent/MX2009004027A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La sobreexpresión del factor de crecimiento endotelial vascular (VEGF) se asocia con una variedad de condiciones que implican angiogénesis aberrante. Se describen en la presente los anticuerpos completamente humanos que enlazan específicamente VEGF humano e inhiben VEGF enlazado a VEGF-R1 y VEGF-R2, y por lo tanto inhiben la señalización de VEGF. Con base en su capacidad para inhibir la señalización de VEGF, los anticuerpos descritos en la presente pueden usarse para tratar angiogénesis y condiciones asociadas con angiogénesis tanto in vivo como in vitro.
MX2009004027A 2006-10-20 2007-10-22 Anticuerpos anti factor de crecimiento endotelial vascular completamente humanos y metodos de uso. MX2009004027A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85326006P 2006-10-20 2006-10-20
PCT/US2007/082164 WO2008133706A2 (en) 2006-10-20 2007-10-22 Fully human anti-vegf antibodies and methods of using

Publications (1)

Publication Number Publication Date
MX2009004027A true MX2009004027A (es) 2009-09-28

Family

ID=39926241

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004027A MX2009004027A (es) 2006-10-20 2007-10-22 Anticuerpos anti factor de crecimiento endotelial vascular completamente humanos y metodos de uso.

Country Status (7)

Country Link
US (1) US20110076279A1 (es)
EP (1) EP2086583A4 (es)
JP (1) JP2010507594A (es)
CN (1) CN102006885A (es)
CA (1) CA2666974A1 (es)
MX (1) MX2009004027A (es)
WO (1) WO2008133706A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0717431A2 (pt) * 2006-09-29 2013-11-12 Oncomed Pharm Inc Composições e métodos de diagnóstico e tratamento do câncer
WO2009055343A2 (en) * 2007-10-22 2009-04-30 Schering Corporation Fully human anti-vegf antibodies and methods of using
KR101093717B1 (ko) * 2008-11-26 2011-12-19 한국생명공학연구원 Ｖｅｇｆ―특이적인 인간항체
WO2010124009A2 (en) * 2009-04-21 2010-10-28 Schering Corporation Fully human anti-vegf antibodies and methods of using
CN102459346B (zh) * 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
CN102002104A (zh) * 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
EP2488204B1 (en) 2009-10-16 2016-04-06 Oncomed Pharmaceuticals, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
CN102167740B (zh) * 2010-02-25 2014-06-04 上海百迈博制药有限公司 一种全人源抗vegf单克隆抗体、其制备方法及用途
US20120225081A1 (en) * 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
CN102757495A (zh) * 2011-04-26 2012-10-31 中国人民解放军第二军医大学 一种全人源抗vegf抗体、其制备方法及用途
CN102875676B (zh) * 2011-07-13 2014-11-05 无锡天演生物技术有限公司 全人源抗人vegf单抗分子及其应用
HUE061002T2 (hu) 2011-09-23 2023-04-28 Mereo Biopharma 5 Inc VEGF/DLL4-kötõ ágensek és alkalmazásaik
JP6371294B2 (ja) 2012-10-31 2018-08-08 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｄｌｌ４アンタゴニストによる処置の方法およびモニタリング
WO2014104406A1 (ja) * 2012-12-27 2014-07-03 学校法人慶應義塾 骨粗鬆症治療剤及び治療剤のスクリーニング方法
US20160130336A1 (en) * 2013-12-31 2016-05-12 Development Center For Biotechnology Anti-vegf antibodies and use thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
DK3212233T3 (da) 2014-10-31 2020-07-27 Oncomed Pharm Inc Kombinationsterapi til behandling af sygdom
CA2999160A1 (en) 2015-09-23 2017-03-30 Oncomed Pharmaceuticals, Inc. Methods and compositions for treatment of cancer
JPWO2017094733A1 (ja) 2015-11-30 2018-09-13 日産化学株式会社 分子標的医薬に結合するｄｎａアプタマー及びそれを用いる分子標的医薬の検出方法
EP3397276A4 (en) 2015-12-30 2019-12-18 Kodiak Sciences Inc. ANTIBODIES AND CONJUGATES THEREOF
US10919958B2 (en) * 2016-08-23 2021-02-16 Medimmune Limited Anti-VEGF-A antibodies and uses thereof
JP7436365B2 (ja) 2017-12-29 2024-02-21 エフ． ホフマン－ラ ロシュ アーゲー 抗ｖｅｇｆ抗体及び使用の方法
WO2020127864A1 (en) * 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Method for improving inhibition of vegf-binding to vegf-r1 of an anti-vegf antibody
CN114174335B (zh) * 2019-07-19 2023-12-15 神州细胞工程有限公司 一种人源化vegfr2抗体及其应用
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
CN116265015A (zh) * 2021-12-16 2023-06-20 石药集团中奇制药技术（石家庄）有限公司 多西他赛白蛋白组合物与vegf抑制剂或vegfr抑制剂的组合及其用途
WO2023192842A2 (en) * 2022-03-30 2023-10-05 Orimabs Ltd. Anti-psma antibodies, variants, and uses thereof
CN115850470B (zh) * 2022-12-12 2023-07-07 三门峡市眼科医院 Vegf抗体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1787999B1 (en) * 1997-04-07 2010-08-04 Genentech, Inc. Anti-VEGF antibodies
ES2295228T3 (es) * 2000-11-30 2008-04-16 Medarex, Inc. Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos.
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
EP1439192A1 (en) * 2003-01-15 2004-07-21 Xerion Pharmaceuticals AG Neuropilin-1 inhibitors
EP1851315B1 (en) * 2005-02-02 2013-12-25 University of Massachusetts Human antibodies against rabies and uses thereof
WO2009055343A2 (en) * 2007-10-22 2009-04-30 Schering Corporation Fully human anti-vegf antibodies and methods of using

Also Published As

Publication number Publication date
CA2666974A1 (en) 2008-11-06
WO2008133706A2 (en) 2008-11-06
EP2086583A4 (en) 2010-05-26
WO2008133706A3 (en) 2009-02-19
JP2010507594A (ja) 2010-03-11
US20110076279A1 (en) 2011-03-31
WO2008133706A8 (en) 2010-05-14
EP2086583A2 (en) 2009-08-12
CN102006885A (zh) 2011-04-06

Similar Documents

Publication Publication Date Title
MX2009004027A (es) Anticuerpos anti factor de crecimiento endotelial vascular completamente humanos y metodos de uso.
MX2010004327A (es) Anticuerpos anti-vegf completamente humanos y metodos de uso.
WO2010124009A3 (en) Fully human anti-vegf antibodies and methods of using
MX2011013781A (es) Anticuerpos anti-vegf y sus usos.
MX2011011670A (es) Inmunoglobulinas de dominio variable dual y usos de las mismas.
EA200801521A1 (ru) Лиганды, которые обладают специфичностью связывания к vegf и/или egfr, и способы их применения
MX2012005037A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
MX2012004415A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
SG178602A1 (en) Dual variable domain immunoglobulins and uses thereof
MX2012001262A (es) Inmunoglobulinas de dominio variable doble y usos de las misma.
MX2011011669A (es) Inmunoglobulinas de dominio variable dual y usos de las misma.
WO2010005524A3 (en) Abdominal aortic aneurysms: systems and methods of use
PH12014502419A1 (en) Specific binding proteins and uses thereof
EP2373692A4 (en) IMMUNOGLOBULINE WITH DOUBLE VARIABLE DOMAIN AND ITS USE
EP2590671A4 (en) IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAIN AND USES THEREOF
MY156458A (en) Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
TN2012000040A1 (en) High affinity human antibodies to human angiopoietin -2
MY165273A (en) Anti-cd48 antibodies and uses thereof
MX2013004979A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
MX2013002270A (es) Inmonoglubinas de dominio variable doble y usos de las mismas.
TW201206473A (en) Dual variable domain immunoglobulins and uses thereof
TW200736275A (en) Methods and compositions for treating allergic diseases
WO2011066417A3 (en) Antibodies and conjugates for modulators of angiogenesis
MX2015006859A (es) Anticuerpos anti-vegf y sus usos.
WO2011041319A3 (en) Specific binding proteins and uses thereof

Legal Events

Date Code Title Description
HH Correction or change in general